학술논문
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial
Document Type
Article
Author
Lorusso, D.; Scambia, G.; Xiang, Y.; Hasegawa, K.; Leiva, M.; Ramos-Elias, P.; Acevedo, A.; Sukhin, V.; Cloven, N.; Pereira de Santana Gomes, A.J.; Contreras Mejía, F.; Reiss, A.; Ayhan, A.; Lee, J.-Y.; Saevets, V.; Zagouri, F.; Gilbert, L.; Sehouli, J.; Tharavichitkul, E.; Lindemann, K.; Lazzari, R.; Chang, C.-L.; Lampé, R.; Zhu, H.; Oaknin, A.; Christiaens, M.; Polterauer, S.; Usami, T.; Li, K.; Yamada, K.; Toker, S.; Keefe, S.M.; Pignata, S.; Duska, L.R.
Source
In: The Lancet . (The Lancet, 6 April 2024, 403(10434):1341-1350)
Subject
Language
English
ISSN
1474547X
01406736
01406736